NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
High risk Neuroblastoma (HR NB) remains a challenge in pediatric oncology, accounting for 15% of all pediatric cancer deaths. While most patients are able to attain remission, approximately 50% will relapse. Once relapse occurs, there is currently no curative treatment for these children, and the 5-year survival rate for these children is
No. 1 in Brain Surgery. Any Way You Look At It. | NYU Langone Health
NYU Langone has the highest survival rates for brain surgery and is the No. 1 hospital in the country for neurology and neurosurgery.
Non-contact specular microscopy measurement of peripheral and central endothelial cell density after cataract surgery
This study aims to investigate post-surgical corneal endothelial cell migration and healing using non-contact specular microscopy and tomography. 80 patients receiving cataract surgery will have corneal imaging taken pre-operatively, one day post-operatively, and several weeks post-operatively. Endothelial cell density and corneal thickness will be correlated and analyzed pre- and post-operatively.
Non-Discrimination Policy | NYU Langone Health
NYU Langone Health has a strict non-discrimination policy that applies to all members of the NYU Langone Health community and its patients.
Non-Hodgkin Lymphoma | NYU Langone Health
Doctors at Perlmutter Cancer Center use genetic testing to determine the best treatment for non-Hodgkin lymphoma.
Non-Hodgkin Lymphoma in Children | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone diagnose and treat childhood non-Hodgkin lymphoma.
Non-invasive biomarkers for neonatal outcomes in preterm infants
Despite modern advances that have greatly improved the health outcomes for preterm infants, the field of neonatology still lacks reliable prognostic tools for many disorders. Noninvasively-obtained samples (such as blood, trach aspirate, urine, saliva and stool samples) contain a wealth of biologic information in the form of DNA, RNA, proteins, and metabolites that can predict neonatal outcomes. Exosomes are small, membrane-bound extracellular vesicles (EVs) that are released by a variety of cells and involved in several cell-to-cell communication pathways. A proposed mechanism by which exosomes mediate cell signaling is via microRNAs (miRNAs), which are small, non-coding RNA segments that silence complementary messenger RNA (mRNA) segments. While exosomes have been characterized in biofluids from adults, few studies have examined the diagnostic value of biofluid exosomes.The objective of this study is to determine whether exosomes can be isolated from neonatal blood, urine, trach aspirate, saliva and stool samples, and if so, whether specific biomarkers (such as exosomal miRNAs) are associated with distinct neonatal pathologies such as chronic lung disease of prematurity (BPD: Bronchopulmonary dysplasia) or other neonatal inflammatory conditions. This is significant because findings could revolutionize the way preterm infants in neonatal intensive care units (NICUs) are monitored at the bedside. This exploratory, prospective study will be conducted with samples collected from the NYU Winthrop Hospital NICU. Specifically, we will measure biomarkers from non-invasive samples (Blood, urine, saliva and stool samples) in two groups; 1) preterm infants
Non-invasive neurosurgical planning with Random Matrix Theory MRI
The primary focus of this study will be to develop and validate an Radiofrequency (RF) coil-based multimodal Random Matrix Theory (RMT) denoising/reconstruction for brain mapping of tumor patients. The objective of this study is to determine whether RMT combined with these new software techniques using can produce meaningful structural and physiological information that can serve to improve our understanding of various disease processes in the clinical setting.
Non-Invasive Salivary Biomarkers in Full Term Neonates
Despite modern advances that have greatly improved the health outcomes for infants, the field of neonatology still lacks reliable prognostic tools for many disorders. Non-invasively-obtained samples (such as saliva) contains a wealth of biologic information in the form of DNA, RNA, proteins, and metabolites that can predict neonatal outcomes. Exosomes are small, membrane-bound extracellular vesicles (EVs) that are released by a variety of cells and involved in several cell-to-cell communication pathways. A proposed mechanism by which exosomes mediate cell signaling is via microRNAs (miRNAs), which are small, non-coding RNA segments that silence complementary messenger RNA (mRNA) segments. While exosomes have been characterized in biofluids from adults, few studies have examined the diagnostic value of these biofluid exosomes.The objective of this study is to determine whether exosomes can be isolated from full-term neonatal saliva samples, and if so, whether specific biomarkers (such as exosomal miRNAs) can be further characterized. This is significant because findings could suggest ways to measure biomarkers non-invasively in neonates.This exploratory, prospective study will be conducted with samples collected from the NYU Langone – Long Island Outpatient Pediatric Clinic. Specifically, we will measure biomarkers from non-invasive samples (saliva) in full-term infants >37 weeks gestation (n=40) who were never admitted to the Neonatal Intensive Care Unit. Neonates can be enrolled in the first week of life at their first well-baby visit to the Pediatric Clinic. Samples will then be collected at every routine well-baby visit starting in the 2nd week for the first 4 weeks of life. Mouth suctioning to collect saliva samples will be performed specifically for research. All samples will be transported to the PI’s laboratory and processed for experimentation. The biomarkers examined in the lab will then be correlated to neonatal clinical outcomes obtained via medical record review.
Non-Small Cell Lung Cancer | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center diagnose and treat people who have non-small cell lung cancer.